Results 131 to 140 of about 48,812 (228)
IJU Case Reports, Volume 9, Issue 6, November 2026.ABSTRACT Introduction Renal cell carcinoma (RCC) is the most common primary site of pancreatic metastases, and complete resection confers a favorable prognosis. Lenvatinib plus pembrolizumab (LEN + PEM) is standard first‐line therapy for advanced RCC; however, induction therapy before resection of pancreatic metastasis has not been reported.
Yuta Kaneko +9 more
wiley +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Laura Schreieder +7 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang +10 more
wiley +1 more source
The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy
Cancer Medicine, Volume 15, Issue 10, October 2026.ABSTRACT Cancer genomes shape the immune landscape within the tumor microenvironment (TME), thereby influencing host antitumor immunity. Identifying somatic mutations that modulate the TME is critical for selecting patients most likely to benefit from immunotherapy.
Kyung‐Jin Cho, Byungho Lim
wiley +1 more source
Cancer, Volume 132, Issue 19, 1 October 2026.ABSTRACT The objective of this systematic review and meta‐analysis was to evaluate the validity of progression‐free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma.
Russell Leong +7 more
wiley +1 more source
Cancer Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav +4 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia +11 more
wiley +1 more source
MedComm, Volume 7, Issue 10, October 2026.Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen +11 more
wiley +1 more source
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer
MedComm, Volume 7, Issue 10, October 2026.Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta +2 more
wiley +1 more source